Alzheimer’s genetic risk factor CASS4 controls microglial focal adhesion biology and amyloidosis
Adeline E. Walsh, Benjamin A. Davis, Joshua D. Samuels, William A. Mills, Jessica M. Thanos, Alexis M. Johnson, Katelyn A. Moore, Michael A. Puchalski, Eric J. Steacy, Benjamin W. Wendell, Amélie Daugherty-Lopès, Adrian A. Shimpi, Ukpong B. Eyo, John R. LukensRecent genome-wide association studies have identified numerous Alzheimer’s disease (AD) risk genes enriched in microglia, including Crk-associated substrate (Cas) scaffold protein family member 4 (CASS4), which encodes the adaptor protein CASS4. Despite its strong genetic association with AD, the role of CASS4 in disease remains poorly understood. Here, we show that full-body Cass4 deletion in 5xFAD mice increases amyloid-β (Aβ) deposition, neuronal dystrophy, and cognitive deficits. Since microglia are the predominant brain-resident cells expressing Cass4, we investigated its role in microglial responses to Aβ pathology. Loss of CASS4 impaired microglial mobilization to Aβ plaques and reduced plaque compaction. Phosphoproteomic analysis of purified microglia revealed marked disruption of focal adhesion signaling following Cass4 deletion. Consistent with this, CASS4 deficiency abrogated in vivo microglial recruitment to injury and in vitro wound healing responses, two processes that are centrally orchestrated by focal adhesion biology. Together, these findings identify CASS4 as a critical regulator of microglial function and focal adhesion biology and suggest that CASS4 may represent a therapeutic target for AD.